Tukov, Francis Fonyuy
Novartis (Switzerland)
3 papers on CoChatORCID 0000-0002-0838-864X
Most cited papers
- Verified
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Chand, D., Mohr, F., McMillan, H., Tukov, F. F., Montgomery, K., Kleyn, A., Sun, R., Tauscher-Wisniewski, S., Kaufmann, P., & Kullak-Ublick, G. (2021) · Journal of Hepatology
Neurogenetic and Muscular Disorders ResearchDrug-Induced Hepatotoxicity and Protection
Cited by 306
- Verified
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
Day, J. W., Mendell, J. R., Mercuri, E., Finkel, R. S., Strauss, K. A., Kleyn, A., Tauscher-Wisniewski, S., Tukov, F. F., Reyna, S. P., & Chand, D. H. (2021) · Drug Safety
Neurogenetic and Muscular Disorders ResearchVirus-based gene therapy research
Cited by 119
- Verified
Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa
MacLachlan, T. K., Milton, M. N., Turner, O., Tukov, F., Choi, V. W., Penraat, J., Hanks, S. M., Vrouvlianis, J., Leehy, B., Li, H., et al. (2018) · Molecular Therapy - Methods & Clinical Development
Retinal Development and DisordersVirus-based gene therapy research
Cited by 40
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free